| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Licensing revenue | 0 | 0 | - | 850 |
| Research and development | 12,826 | 16,415 | 8,612 | 11,174 |
| General and administrative | 2,991 | 4,651 | 3,627 | 4,721 |
| Total operating expenses | 15,817 | 21,066 | 12,239 | 15,895 |
| Loss from operations | -15,817 | -21,066 | -12,239 | -15,045 |
| Interest income | 1,558 | 1,185 | 1,758 | 1,969 |
| Us-gaap_incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest | - | - | - | -13,076 |
| Net loss | -14,259 | -19,881 | -10,481 | -13,076 |
| Unrealized gain on marketable securities | 66 | 18 | 577 | -1 |
| Comprehensive loss | -14,193 | -19,863 | -9,904 | -13,077 |
| Net loss per share - basic and diluted (in dollars per share) | -0.08 | -0.14 | -0.08 | -0.1 |
| Us-gaap_weightedaveragenumberofsharesoutstandingbasic | 168,782,000 | 138,282,000 | 137,589,000 | 137,589,000 |
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. (CMPX)